Yedidya Saiman, MD, PhD, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University, offered insight to the Philadelphia Inquirer on Rezdiffra, or resmetirom, which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of scarring and inflammation caused by abnormal accumulations of fat in the liver. The condition is known as metabolic dysfunction-associated steatohepatitis (MASH), or fatty liver disease. Dr. Saiman was not involved in the study of Rezdiffra.
IMPORTANT: Beginning at 8:00 AM on July 22, Temple University Hospital – Main Campus (Broad and Ontario Streets) will no longer provide Labor and Delivery services. All childbirth services will be relocated to our new hospital location.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH